Tekla Life Sciences Investors (HQL) 19.26 $HQL Tekla

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tekla Life Sciences Investors (HQL) 19.26 $HQL

Tekla Healthcare Opportunities Fund Paid Distribution
BusinessWire - Fri Jul 29, 10:11AM CDT
On July 29, 2016, Tekla Healthcare Opportunities Fund paid a monthly stock distribution of $0.1125 per share. It is currently estimated that this distribution is derived from net investment income. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is $13,621,091, of which $2,197,382 represents net unrealized depreciation of portfolio securities.
HQL: 19.26 (+0.12), THQ: 17.80 (+0.14), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla World Healthcare Fund Paid Distribution
BusinessWire - Fri Jul 29, 10:11AM CDT
On July 29, 2016, Tekla World Healthcare Fund paid a monthly stock distribution of $0.1167 per share. It is currently estimated that this distribution is derived from net investment income. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$48,763,007, of which $77,916,550 represents net unrealized depreciation of portfolio securities.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Funds Announce Results of Joint Annual Shareholders Meeting
BusinessWire - Tue Jun 14, 1:02PM CDT
The Boards of Trustees of Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) are pleased to announce the results from the Funds' annual shareholder meeting held today.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Life Sciences Investors Paid Distribution
BusinessWire - Fri Jun 10, 9:48AM CDT
On June 10, 2016, Tekla Life Sciences Investors paid a distribution of $0.37 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $92,430,063, of which $96,890,977 represents net unrealized appreciation of portfolio securities.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Healthcare Investors Paid Distribution
BusinessWire - Thu Mar 31, 11:59AM CDT
On March 31, 2016, Tekla Healthcare Investors paid a distribution of $0.61 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $209,865,139, of which $197,524,925 represents net unrealized appreciation of portfolio securities.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Life Sciences Investors (the "Fund" announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Investors (the "Fund" announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
THQ: 17.80 (+0.14), HQL: 19.26 (+0.12), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

Tekla Healthcare Opportunities Fund Announces Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Opportunities Fund (the "Fund" announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
HQL: 19.26 (+0.12), THQ: 17.80 (+0.14), THW: 14.63 (+0.04), HQH: 26.41 (+0.23)

H&Q Life Sciences Investors Has Returned 26.5% Since SmarTrend Recommendation (HQL)
Comtex SmarTrend(R) - Wed Feb 03, 6:25PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 26.52% as of today's recent price of $17.64.
HQL: 19.26 (+0.12)

22.1% Return Seen to Date on SmarTrend H&Q Life Sciences Investors Call (HQL)
Comtex SmarTrend(R) - Wed Jan 27, 5:16PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 22.14% as of today's recent price of $18.69.
HQL: 19.26 (+0.12)

H&Q Life Sciences Investors Down 25.6% Since SmarTrend Downtrend Call (HQL)
Comtex SmarTrend(R) - Wed Jan 20, 11:13AM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 25.56% as of today's recent price of $17.87.
HQL: 19.26 (+0.12)

H&Q Life Sciences Investors Shares Down 15.4% Since SmarTrend's Sell Call (HQL)
Comtex SmarTrend(R) - Tue Jan 12, 5:08PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 15.35% as of today's recent price of $20.32.
HQL: 19.26 (+0.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Neurotrope, Inc. Achieves New Milestone with Stock Surge

Updated Category News Views 147

Neurotrope, Inc. Reaches New Stock Milestone Neurotrope, Inc. (NASDAQ: NTRP) has recently achieved a significant milestone in the stock market, soaring to a 52-week high with its price reaching $7.00. This impressive climb indicates a remarkable 124.95% increase over the past year, showcasing strong investor interest and confidence in the company's future prospects. The...

Continue Reading
Lil Nas X's Legal Challenges and Public Struggles Unfold

Updated Category News Views 284

Lil Nas X Pleads Not Guilty to Serious Charges Grammy-winning musician Lil Nas X has recently made headlines for pleading not guilty to multiple felony charges stemming from an incident involving police officers. This situation arose when he was found walking unclothed on the streets of Los Angeles. Understanding the Legal Battle Ahead The rapper, known legally as Montero...

Continue Reading
Exyte's Strategic Acquisition of TTP Group Enhanced Operations

Updated Category News Views 51

Exyte Acquires TTP Group to Strengthen Engineering Expertise Exyte, a leader in high-tech facility engineering, has officially completed the acquisition of TTP Group, enhancing its operations and expertise especially in the biopharma and life sciences sectors. This acquisition marks a significant milestone for Exyte as it melds TTP's capabilities with its own, aiming to...

Continue Reading
Unveiling Health Innovations: Zepp Health at CES 2024 Events

Updated Category News Views 372

Zepp Health Showcases Innovative Technologies at CES Zepp Health Corporation (NYSE: ZEPP), a leader in health technology and smart wearables, is excited to announce its participation in significant media events like Pepcom and ShowStoppers at CES. These occasions will showcase Zepp Health's latest advancements in smart wearables and health technologies, aimed at...

Continue Reading
Meridian Locks $186M Loan for NJ Condo Project

Updated Category News Views 163

New Jersey's Coastline Gets a $186 Million Facelift Here's a move that'll shake the Jersey Shore awake: Meridian Capital Group's just put their money where the sand is with a massive $186 million scoop for a new high-end condominium project in Asbury Park. You couldn't make up a better setting—a beachfront spot ripe for some high-end living. But let's not get too...

Continue Reading